Table 1.

Baseline demographic data of patients with epidermal growth factor receptor (EGFR)‐mutated lung adenocarcinoma and brain metastases (BM) treated with EGFR–tyrosine kinase inhibitor (TKI) alone or with whole‐brain radiotherapy (WBRT)

Characteristic	EGFR‐TKI alone (n = 79)		EGFR‐TKI plus WBRT (n = 53)		P‐value
	No.	%	No.	%
Age, years
Median	52		52
Range	29–75		31–74
Age distribution, years
<65	63	79.7	44	83.0	0.585
≥65	16	20.3	9	17.0
Gender
Male	27	34.2	24	45.3	0.112
Female	52	65.8	29	54.7
Smoking status
Never	61	77.2	36	67.9	0.154
Former	18	22.8	17	32.1
Primary tumor location
Left lung	30	38.0	20	37.7	1.000
Right lung	49	62.0	33	62.3
EGFR mutation status
Del‐19	44	55.7	28	52.8	0.670
L858R	35	44.3	25	47.2
BM number
≤3	24	30.4	11	20.8	0.144
>3	55	69.6	42	79.2
Intracranial symptoms
Without	51	65.6	16	30.2	0.001
With	28	34.4	37	69.8